Local Open-Label Access Study For Patients Who Completed A1481244 Study In Brazil
Status:
No longer available
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to provide sildenafil therapy to patients who completed the
A1481244 study for the treatment of PAH, and reside in Brazilian States where Revatio™ is not
supplied by Health Secretary, and are judged by the Investigator to derive clinical benefit
from continued treatment with Sildenafil. It will be supplied until patient gets access to
Sildenafil through Brazilian State Health Secretary from where patient resides.
Details
Lead Sponsor:
Pfizer Pfizer's Upjohn has merged with Mylan to form Viatris Inc.